leadf
logo-loader
viewBioSig Technologies, Inc.
(
NASDAQ:BSGM
)

BioSig to install PURE EP System for evaluation at St. Elizabeth’s Medical Center in Boston

CEO Kenneth Londoner said the deal marks the company’s 13th hospital partner as it remains on track to achieve its 2021 goals of targeted market expansion

BioSig
The PURE EP is a US FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology

BioSig Technologies Inc said it would install a PURE EP System for evaluation at St. Elizabeth’s Medical Center in Boston. 

The company said it initiated the new evaluation program under the leadership of Dr. Michael Orlov and aims to assess the PURE EP System during a series of physiologic pacing procedures. 

Physiologic pacing is an emerging pacing technique designed to activate the normal cardiac conduction system and synchronize contraction of the ventricles. This approach to pacing the heart has demonstrated improved clinical and hemodynamic benefits beyond standard pacing techniques. 

READ: BioSig installs PURE EP system at New York hospital as part of northeast commercial launch

“The physiologic pacing procedure could benefit from advanced signal information to optimize lead placement and improve procedural outcomes,” said BioSig CEO Kenneth Londoner in a statement. “We look forward to combining our cardiac signal acquisition technology with advanced pacing therapies to treat more cardiac rhythm disorders.”

Londoner added: “This marks our 13th hospital partner, and we remain on track to achieve our 2021 goals of targeted market expansion.”

The PURE EP is a US FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, over 60 physicians have completed over 1,300 patient cases with the PURE EP System across 12 clinical sites.

The company recently completed its first multi-centered, prospective clinical trial and presented preliminary clinical data during the annual Heart Rhythm 2021 convention in July in Boston.

BioSig is in a focused commercial launch of the PURE EP System in the Northeast, Texas, and Florida and is in regular use in some of the country’s leading centers of excellence, including the Mayo Clinic in Rochester, Minnesota, and St. David’s Medical Center in Austin, Texas.

One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the US. According to the Centers for Disease Control and Prevention, atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in about $6 billion in healthcare spending annually.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: BioSig Technologies, Inc.

Follow
NASDAQ:BSGM

Price: 3.04 USD

Market Cap: $106.17 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BioSig Technologies taps medical-device industry executive James Barry as...

BioSig Technologies Inc CEO Kenneth Londoner tells Proactive the group has appointed Dr James Barry as an independent board director. Londoner says Dr Barry has more than 30 years of experience in the medical device industry as an executive and corporate board director. He spent the majority...

5 days ago

2 min read